ENTRY       D04923                      Drug
NAME        Mepolizumab (USAN/INN);
            Mepolizumab (genetical recombination) (JAN);
            Nucala (TN)
PRODUCT     NUCALA (GlaxoSmithKline LLC)
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 2290
            ATC code: R03DX09
            Product: D04923<JP/US>
EFFICACY    Antiasthmatic, Anti-IL-5 antibody
  DISEASE   Asthma, eosinophilic phenotype [DS:H00079]
  TYPE      Monoclonal antibody
TARGET      IL5 [HSA:3567] [KO:K05428]
  PATHWAY   hsa04060(3567)  Cytokine-cytokine receptor interaction
            hsa04630(3567)  JAK-STAT signaling pathway
            hsa04640(3567)  Hematopoietic cell lineage
            hsa05310(3567)  Asthma
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
                R03DX Other systemic drugs for obstructive airway diseases
                 R03DX09 Mepolizumab
                  D04923  Mepolizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Respiratory Tract Agents, Other
               Immunomodulators
                Mepolizumab
                 D04923  Mepolizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D04923  Mepolizumab (USAN/INN); Mepolizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D04923  Mepolizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D04923  Mepolizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL5
                 D04923  Mepolizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04923
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04923
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04923
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04923
DBLINKS     CAS: 196078-29-2
            PubChem: 47206675
///
